| Neuroendocrine Tumors |
2014-003856-30: Trial for patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR. |
|
|
| Ongoing | 4 | 50 | Europe | SANDOSTATIN LAR, Injection, Sandostatine Long Acting Repeatable (LAR) 10, 20, 30 mg | Cliniques Universitaires Saint Luc, Cliniques Universitaires Saint Luc, Novartis pharma SA/NV | The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreotide LAR., To observe the change from baseline in the incidence of diarrhea and flushing in relation to the serum octreotide level (level in the blood) independently of the dose variations of octreotide LAR., Diseases [C] - Cancer [C04] | | | | |
2018-000398-64: Comparison of PET (radiological test) with 18F-FDG and with 68Ga-DOTA-peptides in advanced neuroendocrine tumors Comparativa de PET (prueba radiológica) con 18F-FDG y con 68Ga-DOTA-péptidos en los tumores neuroendocrinos avanzados |
|
|
| Ongoing | 4 | 30 | Europe | Kit for radiopharmaceutical preparation, SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation | Vall d' Hebron Institute of Oncology (VHIO), Advanced Accelerator Applications | Gastroenteropancreatic neuroendocrine tumor disease Tumores neuroendocrinos gastroenteropancreáticos, Gastroenteropancreatic neuroendocrine tumor disease Tumores neuroendocrinos gastroenteropancreáticos, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
2017-002561-21: Study of addition of belinostat to chemotherapy before surgery in patients with Thymic Epithelial Tumors (TET) |
|
|
| Ongoing | 3 | 100 | Europe | Belinostat, Powder for solution for infusion, Beleodaq (in the USA) | IFCT, Onxeo | Locally advanced potentially resectable Thymic Epithelial Tumors, Locally advanced Thymus Tumors, Diseases [C] - Cancer [C04] | | | | |
2011-005562-38: Safety and Efficacy of peripheral blood stem cell transplantation using specifically purified stem cell preparations derived from patient family members in paediatric and adult patients Sicherheit und Wirksamkeit der Blutstammzelltransplantation mit spezifisch aufgereinigten Stammzellpräparaten von Famililienmitgliedern der Patienten als Spender bei Kindern und Erwachsenen |
|
|
| Ongoing | 2 | 60 | Europe | TCRabCD19PBSC, TCRabCD19PBSC_cryo, Suspension for injection | Miltenyi Biotec GmbH, Miltenyi Biotec GmbH | Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor. Hämatologische oder nicht-hämatologische maligne Erkrankungen oder nicht bösartige Erkrankungen, die einer allogenen Blutstammzelltransplantation eines haploidentischen Spenders bedürfen., Severe diseases requiring allogenic blood stem cell transplantation. Schwere Erkrankungen, die einer allogenen Blutstammzelltransplantation bedürfen., Diseases [C] - Cancer [C04] | | | | |
2012-003939-27: Objective evaluation of the effects of pasireotide on gastrointestinal and colorectal transit times, rectal wall properties, and postprandial response in patients with carcinoid diarrhea Undersøgelse af pasireotids effekt på transittiden gennem tarmen, endetarmens egenskaber samt respons efter fødeindtag hos patienter med diare grundet en neuroendokrin tumor |
|
|
| Ongoing | 2 | 15 | Europe | Signifor 0.6 mg s.c., Signifor 0.6 mg s.c. | Klaus Krogh, Novartis, Aarhus University | Patients with neuroendocrine tumors and carcinoid diarrhea | | | | |
2011-003226-27: A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma (called UKMCC-01) |
|
|
| Ongoing | 2 | 25 | Europe | Pazopanib, Votrient, Votrient | University of Birmingham, Cancer Research UK, GlaxoSmithKline | Metastatic Merkel Cell Carcinoma | | | | |
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
NCT02327468: Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers |
|
|
| Recruiting | 1 | 54 | US | INO-1400, hTERT, INO-9012, IL-12 | Inovio Pharmaceuticals, Abramson Cancer Center of the University of Pennsylvania, University of North Carolina, Thomas Jefferson University, Wayne State University | Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Squamous Cell Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Cancer | 12/17 | 04/18 | | |
NCT03529539: Expanded Access for PSV Personalized Oncolytic Viruses |
|
|
| No Longer Available | N/A | | NA | PSV | EpicentRx, Inc. | Cancer | | | | |